Stock ALOPM ONCODESIGN PRECISION MEDICINE
Add to a list
To use this feature you must be a member
Log inSign up

Oncodesign Precision Medicine Share Price

Equities

ALOPM

FR001400CM63

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 16:12:53 03/05/2024 BST 		5-day change 1st Jan Change
1.435 EUR -2.71% Intraday chart for Oncodesign Precision Medicine -3.37% -20.72%
01-25 Oncodesign Precision Medicine: fundraising on the horizon CF
01-25 Oncodesign Precision Medicine Receives ERDF Fund Totalling ?2.1 Million for its Comete Program CI

Financials

Sales 2023 1.1M 1.18M 94.4M Sales 2024 * 1M 1.08M 85.82M Capitalization 23.94M 25.76M 2.05B
Net income 2023 * - Net income 2024 * -6 -6.46 -514.93 EV / Sales 2023 21.8 x
Net cash position 2023 * 2.6M 2.8M 223M Net Debt 2024 * 8.5M 9.15M 729M EV / Sales 2024 * 32.4 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-3.78 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 88.38%
More Fundamentals * Assessed data

Chart Oncodesign Precision Medicine

Dynamic Chart

Latest news about Oncodesign Precision Medicine

Oncodesign Precision Medicine: fundraising on the horizon CF
Oncodesign Precision Medicine Receives ERDF Fund Totalling ?2.1 Million for its Comete Program CI
Eurazeo acquires a stake in Oncodesign Services CF
Oncodesign Precision Medicine Société anonyme announced that it has received ?22 million in funding from Eurazeo SE and other investors CI
Oncodesign Precision Medicine Société anonyme acquired Zobio B.v. CI
Oncodesign Precision Medicine Obtains EUR6 Million Loan from Regional Banks MT
Oncodesign Precision Medicine Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers CI
Oncodesign Precision Medicine Société Anonyme Approves the Nomination of Florence Dupré to the Board of Directors CI
Oncodesign launches clinical trial in IBD CF
Oncodesign Precision Medicine Announces Initiation of Phase I of its RIPK2 Inhibitor ODS-101, aNew Therapeutic Agent for IBD CI
Edmond de Rothschild Equity Strategies Management III S.à.r.l acquired 61.58% stakes in Oncodesign Precision Medicine Société anonyme from Philippe Genne and other managers and minority shareholder. CI
Oncodesign Precision Medicine to List Directly on Euronext Access + Paris MT
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme. CI
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme. CI
Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine. CI
More news

Press releases Oncodesign Precision Medicine

Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine BU
Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101 BU
OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments BU
Oncodesign Precision Medicine : OPM publishes its annual results for 2023 and provides an update on its clinical developments PU
Oncodesign Precision Medicine : OPM announces its 2022 results PU
More press releases

News in other languages on Oncodesign Precision Medicine

OPM met à disposition son rapport financier annuel 2023
Degroof Petercam initie la couverture d’Oncodesign Precision Medicine
Oncodesign obtient un financement public de 5,6 millions d'euros
Wall Street à la recherche de son LVMH
En Direct des Marchés : Danone, Sartorius Stedim Biotech, Michelin, TotalEnergies, Vallourec, Nokia, TSMC...
More news

Quotes and Performance

1 day-2.71%
1 week-3.37%
Current month-2.38%
1 month-4.33%
3 months+1.77%
6 months-37.34%
Current year-20.72%
More quotes

Highs and lows

1 week
1.40
Extreme 1.4
1.49
1 month
1.40
Extreme 1.4
1.68
Current year
1.28
Extreme 1.275
2.06
1 year
1.00
Extreme 1
2.39
3 years
0.62
Extreme 0.62
2.50
5 years
0.62
Extreme 0.62
2.50
10 years
0.62
Extreme 0.62
2.50
More quotes

Managers and Directors - Oncodesign Precision Medicine

Managers TitleAgeSince
Philippe Genne CEO
 Chief Executive Officer 62 30/08/22
Jan Hoflack BRD
 Director/Board Member 63 13/09/22
Karine Lignel BRD
 Director/Board Member 55 13/09/22
Members of the board TitleAgeSince
Kamel Besseghir BRD
 Director/Board Member 75 13/09/22
Philippe Genne CEO
 Chief Executive Officer 62 30/08/22
Karine Lignel BRD
 Director/Board Member 55 13/09/22
More insiders

Quotes

Date Price Change Volume
03/05/24 1.435 -2.71% 9,173
02/05/24 1.475 +0.34% 3,077
30/04/24 1.47 +0.68% 24,362
29/04/24 1.46 -1.68% 1,809
26/04/24 1.485 -1.33% 3,601

Real-time Euronext Paris, May 03, 2024 at 04:12 pm

More quotes

Company Profile

Oncodesign Precision Medicine specializes in the research and development of therapeutic and diagnostic solutions in the clinical and preclinical areas of medical oncology. The company aims to discover new targeted therapy molecules for cancers without current solutions, including therapy-resistant and metastatic cancers.
Sector
Biotechnology & Medical Research
Calendar
25/06/2024 - Shareholders Meeting
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.435 EUR
Average target price
2.48 EUR
Spread / Average Target
+72.82%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ONCODESIGN PRECISION MEDICINE Stock Oncodesign Precision Medicine
-20.72% 25.78M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALOPM Stock